Anaplastic Astrocytoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
K
Recruiting
- Advanced Cancer
- +3 more
- EV3D Assay
- Little Rock, Arkansas
- +8 more
2022-03-30
Mar 30, 2022S
Active, not recruiting
- High Grade Glioma
- +3 more
- Regadenoson 0.05mg
- +6 more
- Birmingham, Alabama
- +2 more
2022-04-07
Apr 7, 2022N
Recruiting
- 1p/19q Co-deletion
- +8 more
- IMRT (Intensity-Modulated Radiation Therapy)
- +2 more
- Birmingham, Alabama
- +26 more
2022-04-04
Apr 4, 2022S
Recruiting
- Anaplastic Astrocytoma
- +55 more
- Gemcitabine
- +4 more
- Memphis, TennesseeSt. Jude Children's Research Hospital
2022-04-01
Apr 1, 2022S
Active, not recruiting
- High Grade Glioma
- +6 more
- Encorafenib
- +3 more
- Birmingham, Alabama
- +5 more
2022-03-31
Mar 31, 2022U
Active, not recruiting
- Glioblastoma Multiforme
- +2 more
- Birmingham, AlabamaUniversity of Alabama at Birmingham
2022-03-15
Mar 15, 2022N
Suspended
- Anaplastic Astrocytoma
- +6 more
- Dabrafenib Mesylate
- +2 more
- Birmingham, Alabama
- +113 more
2022-03-26
Mar 26, 2022W
Recruiting
- Glioma
- +8 more
- MRI-guided laser ablation
- +4 more
- Saint Louis, MissouriWashington University School of Medicine
2022-03-15
Mar 15, 2022N
Not yet recruiting
- Anaplastic Astrocytoma
- +4 more
- Radiation Therapy
- Selinexor
- (no location specified)
2022-03-11
Mar 11, 2022G
Recruiting
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Lexington, KentuckyUniversity of Kentucky
2022-03-03
Mar 3, 2022P
Active, not recruiting
- Medulloblastoma
- +7 more
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
- +2 more
- Buffalo, New YorkRoswell Park Comprehensive Cancer Center
2022-02-15
Feb 15, 2022N
Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Active, not recruiting
- Diffuse Astrocytoma
- +21 more
- dabrafenib
- +2 more
- Orange, California
- +56 more
2022-03-02
Mar 2, 2022C
Recruiting
- Central Nervous System Neoplasms
- +22 more
- Bethesda, MarylandNational Institutes of Health
2022-03-01
Mar 1, 2022J
Active, not recruiting
- Glioma
- +3 more
- autologous tumor lysate-pulsed DC vaccination
- +2 more
- Los Angeles, CaliforniaUniversity of Los Angeles, California
2022-02-16
Feb 16, 2022N
Active, not recruiting
- Anaplastic Astrocytoma
- +5 more
- Adavosertib
- +3 more
- Birmingham, Alabama
- +23 more
2022-01-28
Jan 28, 2022U
Active, not recruiting
- Supratentorial Neoplasms, Malignant
- +6 more
- G207
- Birmingham, Alabama
- +1 more
2022-01-28
Jan 28, 2022P
Recruiting
- Glioblastoma Multiforme
- +5 more
- Los Angeles, California
- +12 more
2022-01-27
Jan 27, 2022O
Recruiting
- Glioma, Malignant
- +4 more
- Tampa, FloridaMoffitt Cancer Center
2022-01-11
Jan 11, 2022O
Active, not recruiting
- Anaplastic Astrocytoma
- Recurrent Anaplastic Astrocytoma
- Birmingham, Alabama
- +78 more
2022-01-19
Jan 19, 2022N
Completed
- Glioma
- +7 more
- Neural stem cells loaded with an oncolytic adenovirus
- Duarte, California
- +1 more
2022-01-10
Jan 10, 2022N
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas - 2019
Completed
- Diffuse Intrinsic Pontine Glioma
- +2 more
- Lenalidomide
- XRT, 54-59.4 Gy
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2021-12-30
Dec 30, 2021M
Active, not recruiting
- Malignant Glioma
- +3 more
- Dendritic Cell Vaccine
- +3 more
- Miami, FloridaUniversity of Miami
2021-12-07
Dec 7, 2021N
Active, not recruiting
- Anaplastic Astrocytoma
- +2 more
- Radiation Therapy
- +2 more
- Birmingham, Alabama
- +162 more
2021-10-28
Oct 28, 2021N
Suspended
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Bevacizumab and Carboplatin
- New York, New YorkLenox Hill Brain Tumor Center
2021-10-27
Oct 27, 2021N
Recruiting
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- New York, New YorkLenox Hill Brain Tumor Center
2021-10-27
Oct 27, 2021